leading glp-1 treatments for diabetes 2025 What is the pipeline future medications for obesity? The first of three of

Currently, it is only FDA-approved for the treatment of type 2 diabetes, but is being studied for the treatment of obesity, as it was seen to cause significant weight loss

Read source Enterogastrone

Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice

Advances in Nutrition , 12 (6), 2540-2552

Probiotics : Early research suggests that probioticslive microorganisms in your digestive systemmay promote cells in the intestines to secrete GLP-1, thus improving insulin function

3 These findings move GLP-1s out of the weight-loss drug category and into the category of proven cardiovascular risk-reduction tools